CMS Modified NCD 146 for EDTA Chelation Therapy, Effective March 7, 2026 — What Billing Teams Need to Know

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 146 governing EDTA chelation therapy for atherosclerosis, with an effective date of March 7, 2026. The position hasn't softened — Medicare does not cover this treatment, and billing it will get your claim denied.

This update to the CMS EDTA chelation therapy coverage policy reinforces a long-standing non-coverage position. NCD 146 in the Medicare system classifies EDTA chelation therapy for atherosclerosis, arteriosclerosis, and calcinosis as experimental. No specific CPT or HCPCS codes are listed in the policy document itself, but that doesn't make this change low-stakes — especially if your practice or any providers you support have been billing for chelation services.

Quick-Reference Table

CMS EDTA Chelation Therapy Coverage Criteria and Medical Necessity Requirements 2026

NCD 146 is a National Coverage Determination. That means it applies nationally, across every Medicare Administrative Contractor jurisdiction. There's no regional variation here, no local coverage determination that opens a back door, and no Medicare Advantage plan flexibility on this one for traditional Medicare beneficiaries.

The medical necessity standard for EDTA chelation therapy under Medicare is blunt: there is none. CMS does not recognize EDTA as medically necessary for atherosclerosis, arteriosclerosis, calcinosis, or any similar generalized vascular condition. The policy language is explicit — any such use is "considered experimental."

This matters for your billing team because experimental status under Medicare means the service is non-covered by definition. A claim that is non-covered for experimental reasons is not the same as a claim that lacks prior authorization or fails a frequency limit. You can't appeal your way out of experimental status. You can't get a medical necessity exception. The coverage policy closes that door entirely.

If your practice has been relying on an Advance Beneficiary Notice of Noncoverage (ABN) to shift liability to the patient for EDTA chelation — that approach may hold for some non-covered services, but you need your compliance officer to confirm whether your specific billing situation is structured correctly. Talk to your compliance officer before the effective date if you have any open or recurring claims.

Prior authorization for EDTA chelation under Medicare is not just unavailable — it's irrelevant. CMS won't authorize a service it considers experimental. Prior authorization only applies to covered services. This is not a prior auth issue; it's a coverage issue.

CMS EDTA Chelation Therapy Exclusions and Non-Covered Indications

The non-coverage position here is broad. NCD 146 does not carve out specific sub-indications or leave any atherosclerosis-related use of EDTA open for coverage. The policy covers every use of EDTA as a chelating agent for the following:

The real issue with that "similar generalized conditions" language is that it's intentionally broad. If a provider is billing EDTA chelation for any vascular or mineral-metabolism condition not explicitly FDA-approved, NCD 146 captures it. Don't assume a slightly different diagnosis code changes your exposure here.

The FDA has not approved EDTA chelation for these indications. That's the foundation of the experimental designation. CMS follows FDA approval status closely when making coverage determinations for treatments like this, and without an approved indication, there's no path to coverage under this policy.

Coverage Indications at a Glance

That last row deserves attention. EDTA does have FDA-approved uses — primarily for heavy metal poisoning. NCD 146 does not govern those uses. If your practice bills EDTA chelation for lead poisoning or other approved indications, that claim travels on a different coverage basis entirely. Conflating the two is a billing error that creates unnecessary claim denial risk.

CMS EDTA Chelation Therapy Billing Guidelines and Action Items 2026

CPT, HCPCS, and ICD-10 Codes for EDTA Chelation Therapy Under NCD 146

Policy-Listed Codes

The Centers for Medicare & Medicaid Services did not list specific CPT, HCPCS Level II, or ICD-10-CM codes within NCD 146 as modified. This is not unusual for older NCDs — many were written before code-level specificity became standard practice in coverage determinations.

The absence of listed codes does not reduce your billing risk. It increases it, because there's no code-level safe harbor. Any claim for EDTA chelation therapy applied to atherosclerosis, arteriosclerosis, calcinosis, or a similar condition is subject to this non-coverage determination regardless of what code it carries.

Codes Commonly Associated with Chelation Infusion Services (Not Listed in NCD 146 — For Reference Only)

Your billing team should be aware that chelation therapy services are typically billed using infusion therapy codes. NCD 146 does not list these codes, and we are not attributing coverage or non-coverage status to them based on this policy alone. However, when any of these codes are paired with a diagnosis reflecting atherosclerosis or a similar vascular condition on a Medicare claim, NCD 146 governs coverage — and the answer is non-covered.

Work with your billing consultant to map your actual charge capture against the diagnosis codes present on those claims. The code table question here isn't which procedure codes are listed — it's which diagnosis codes are triggering non-coverage under this NCD.

If you need code-level guidance on how to handle EDTA chelation claims — including which diagnosis codes most commonly trigger this NCD and how to structure ABNs for specific code combinations — that's a conversation for your billing consultant or your Medicare Administrative Contractor's provider outreach team.